Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,995 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group. Suda G, et al. J Gastroenterol. 2017 Oct;52(10):1122-1129. doi: 10.1007/s00535-017-1328-z. Epub 2017 Mar 18. J Gastroenterol. 2017. PMID: 28315983 Clinical Trial.
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N. Sho T, et al. Drugs R D. 2017 Sep;17(3):381-388. doi: 10.1007/s40268-017-0187-7. Drugs R D. 2017. PMID: 28573606 Free PMC article. Clinical Trial.
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. Hepatol Res. 2018 Feb;48(3):E146-E154. doi: 10.1111/hepr.12938. Epub 2017 Aug 10. Hepatol Res. 2018. PMID: 28722780
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. J Gastroenterol. 2019 Jul;54(7):641-649. doi: 10.1007/s00535-019-01556-y. Epub 2019 Feb 18. J Gastroenterol. 2019. PMID: 30778716
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Nakamura A, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N. Kawagishi N, et al. PLoS One. 2018 Dec 21;13(12):e0209615. doi: 10.1371/journal.pone.0209615. eCollection 2018. PLoS One. 2018. PMID: 30576386 Free PMC article.
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Sho T, et al. Intern Med. 2019 Mar 15;58(6):797-802. doi: 10.2169/internalmedicine.1856-18. Epub 2018 Nov 19. Intern Med. 2019. PMID: 30449808 Free PMC article.
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Sho T, et al. Hepatol Res. 2018 Jun;48(7):529-538. doi: 10.1111/hepr.13056. Epub 2018 Feb 15. Hepatol Res. 2018. PMID: 29316051
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. Hepatol Res. 2017 Oct;47(11):1127-1136. doi: 10.1111/hepr.12851. Epub 2017 Jan 31. Hepatol Res. 2017. PMID: 27943523
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Suda G, et al. J Gastroenterol. 2016 Jul;51(7):733-40. doi: 10.1007/s00535-016-1162-8. Epub 2016 Jan 14. J Gastroenterol. 2016. PMID: 26768604 Clinical Trial.
1,995 results
Jump to page
Feedback